Research programme: osteoporosis therapeutics - Exelixis

Drug Profile

Research programme: osteoporosis therapeutics - Exelixis

Alternative Names: Osteoporosis therapeutics research programme - Exelixis

Latest Information Update: 14 Jun 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Class Small molecules
  • Mechanism of Action Cytoplasmic and nuclear receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Osteoporosis

Most Recent Events

  • 14 Jun 2006 No development reported - Preclinical for Osteoporosis in USA (unspecified route)
  • 12 Nov 2004 X-Ceptor Therapeutics has been acquired by Exelixis
  • 29 Sep 2004 Preclinical trials in Osteoporosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top